The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of lacosamide (Vimpat) 10-mg/ml syrup of the anti-epilepsy medicine Vimpat to replace the 15-mg/ml syrup recalled earlier in the year. The recall of the 15-mg/ml syrup began in September 2011 after the marketing-authorisation holder found uneven distribution of the active substance in some bottles, putting patients at risk of inaccurate dosing. This was caused by the active substance forming a precipitate during storage. In assessing the application, the CHMP concluded that there is no risk of the active substance precipitating in the 10-mg/ml syrup, as long as it is not refrigerated.